Association Between Biologic Therapy and Reduced Acute Rhinosinusitis Episodes: A Retrospective Database Study

Objective: To assess whether biologics (dupilumab, mepolizumab, and omalizumab) used for conditions other than chronic rhinosinusitis with nasal polyps (CRSwNP) reduce the frequency of acute bacterial rhinosinusitis (ABRS) episodes. Methods: tests to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Results: = 0.4133) showed a decrease in ABRS episodes though this finding was not statistically significant. Conclusion: Dupilumab appears to significantly reduce ABRS episodes in patients without CRSwNP, suggesting a protective effect on sinonasal health even in patients without chronic sinusitis. Further studies are needed to confirm these effects and to evaluate risks associated with long-term biologic use in non-CRSwNP populations. Level of Evidence: IIIb/IV.